Buy Avanafil Online in Canada

Avanafil is a selective phosphodiesterase type 5 (PDE5) inhibitor. It enhances nitric oxide–mediated vasodilation in the corpus cavernosum and is indicated for the treatment of erectile dysfunction in adult men. In response to sexual stimulation, it improves the ability to achieve and maintain an erection.

What Avanafil is

Avanafil belongs to the PDE5 inhibitor class, which increases cyclic guanosine monophosphate (cGMP) signaling by potentiating nitric oxide–dependent vasodilation. This action promotes penile blood flow during arousal, facilitating erectile function.

Pharmacokinetically, avanafil is rapidly absorbed with an onset of action typically within 15–30 minutes and a duration that supports daily activities yet remains localized to sexual stimulation. Hepatic metabolism via cytochrome P450 3A4 (and to a lesser extent 2C isoforms) produces inactive metabolites, with renal and fecal routes contributing to elimination. The terminal half-life is sufficient to support intermittent dosing while limiting prolonged systemic exposure.

What it is used for

Avanafil is used for the treatment of erectile dysfunction in adult men. It is intended to be taken as needed in the context of sexual activity and is not a cure for the underlying condition. Adequate sexual stimulation is required to achieve an erection.

Patients should be advised that efficacy depends on adequate arousal and that the medication does not produce an erection without sexual stimulation. It is not approved for pediatric use or for women. Contraindications and precautions must be reviewed prior to initiation to minimize risk in susceptible individuals.

Contraindications and precautions

Concomitant use of any nitrate or nitrite therapy is contraindicated due to the risk of clinically meaningful hypotension. This includes nitroglycerin and isosorbide dinitrate, among others, whether administered acutely or chronically. A precautionary period after nitrate exposure is recommended before considering avanafil therapy.

Avanafil should not be used with guanylate cyclase stimulators such as riociguat, due to additive blood-pressure–lowering effects. Caution is advised in patients with significant cardiovascular disease, particularly those with hypotension, recent myocardial infarction, stroke, or life-threatening arrhythmias. In these individuals, a careful risk–benefit assessment is required before initiation.

In patients taking alpha-blockers or other antihypertensives, avanafil may cause additive hypotension. Initiation or dose adjustment should be considered with close monitoring, and patients should be advised about the symptoms of low blood pressure. Severe hepatic impairment or substantial renal impairment may alter avanafil exposure; use in these populations requires individualized assessment. Visual or auditory disturbances, including sudden vision loss (NAION) or sudden hearing decrease, have been reported with PDE5 inhibitors and warrant prompt evaluation. Hypersensitivity to avanafil or excipients is a contraindication, and any signs of an allergic reaction require discontinuation and medical evaluation.

Side effects by frequency

Very common: headache, facial flushing, nasal congestion. These effects are typically mild to moderate and transient.

Common: dizziness, back pain, muscle aches, dyspepsia, and mild edema around the eyelids or periorbital area. A small proportion of patients may report transient vision changes, especially with higher exposures, though this is less frequent than with some older PDE5 inhibitors.

Uncommon to rare: palpitations, hypotension symptoms, epistaxis, nasal irritation, rash, or allergic reactions. Vision or hearing impairment has been reported rarely and requires urgent assessment. Serious adverse events are uncommon with proper use and patient selection, but warrant immediate medical attention if they occur.

Interactions with other substances

Concomitant nitrates or nitrite-containing therapies are strictly contraindicated with avanafil due to the risk of profound and potentially life-threatening hypotension. Similar caution applies to other agents that significantly lower blood pressure.

Strong inhibitors of CYP3A4 (for example, certain azole antifungals, some macrolide antibiotics, and protease inhibitors) markedly increase avanafil exposure and may enhance adverse effects. Co-administration with these agents generally requires avoidance or a significant dose reduction and careful monitoring. Caution is warranted with moderate CYP3A4 inhibitors; a dose adjustment and clinical vigilance are advised.

Alpha-blockers may increase the risk of hypotension when used with avanafil; initiation or dose changes should be performed with careful monitoring of blood pressure and patient tolerance. Alcohol can augment orthostatic hypotension and lightheadedness in some individuals taking PDE5 inhibitors, so patients should limit intake accordingly. Food, particularly high-fat meals, can delay avanafil absorption but does not consistently change overall efficacy; timing relative to sexual activity should be planned accordingly.